116868-93-0

116868-93-0 structure

Name: (Tyr0)-Neurokinin A
Chemical Name: [Tyr0]-Neurokinin A
CAS Number: 116868-93-0
Molecular Formula: C₅₉H₈₉N₁₅O₁₆S
Molecular Weight: 1296.494
Catalog: Research Areas Metabolic Disease
Create Date: 2018-05-21 08:00:00
Modify Date: 2024-01-08 18:22:17
Tyr0-Neurokinin A is a neuropeptide belongs to tachykinin peptide family. Tyr0-Neurokinin A is an agonist of Tacr2. Tyr0-Neurokinin A can be used in the research of insulin resistance, obesity, diabetes[1][2].

Name	[Tyr0]-Neurokinin A
Synonyms	2-Thia-6,9,12,15,18,21-hexaazapentacosa-6,9,12,15,18,21-hexaen-25-oic acid, 23-[[(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-amino-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino]-1-hydroxy-3-(1H-imidazol-5-yl)propylidene]amino]-1-hydroxyhexylidene]amino]-1,3-dihydroxybutylidene]amino]-7,10,13,16,19,22-hexahydroxy-5-(hydroxyiminomethyl)-20-(hydroxymethyl)-14-(1-methylethyl)-8-(2-methylpropyl)-17-(phenylmethyl)-, (5S,8S,14S,17S,20S,23S)- (5S,8S,14S,17S,20S,23S)-23-{[(2S,3R)-2-{[(2S)-6-Amino-2-{[(2S)-2-{[(2S)-2-amino-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-1-hydroxy-3-(1H-imidazol-5-yl)propylidene]amino}-1-hydroxyhexylidene]amino}-1,3-dihydroxybutylidene]amino}-17-benzyl-7,10,13,16,19,22-hexahydroxy-5-[hydroxy(imino)methyl]-20-(hydroxymethyl)-8-isobutyl-14-isopropyl-2-thia-6,9,12,15,18,21-hexaazapentacosa-6,9,12,15,18,21-hexaen-25-oic acid YHKTDSFVGLM-NH2

Description	Tyr0-Neurokinin A is a neuropeptide belongs to tachykinin peptide family. Tyr0-Neurokinin A is an agonist of Tacr2. Tyr0-Neurokinin A can be used in the research of insulin resistance, obesity, diabetes[1][2].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Metabolic Disease Research Areas >> Neurological Disease
Target	Tachykinin Receptor 2 (Tacr2)[2]
References	[1]. Gao X, et al. The study of the conformation and interaction of two tachykinin peptides in membrane mimicking systems by NMR spectroscopy and pulsed field gradient diffusion. Biopolymers. 1999 Oct 15;50(5):555-68. [2]. Gerhart-Hines Zachary, et al. Peptide agonists of Tacr2 for treatment of insulin resistance, diabetes and/or obesity. Patent. WO2021073742.